Everolimus ‐eluting bioresorbable vascular scaffold implantation to treat saphenous vein graft disease, single‐center initial experience

ConclusionsThis first real‐world data on the use of the ABSORB™ BVS in patients with SVG disease shows that its implantation is technically feasible. The observed rate of target lesion revascularization was similar to those observed with drug‐eluting stents in similar settings. Larger studies are required to better define the optimal use of BVS to treat SVG disease.

Source: Journal of Interventional Cardiology - August 1, 2017 Category: Cardiology Authors: Fabien Picard, Guillaume Marquis ‐Gravel, Robert Avram, Hung Q. Ly, Jean‐François Dorval, Serge Doucet, Quentin de Hemptinne, Philippe L. L'allier, Jean‐François Tanguay Tags: ORIGINAL INVESTIGATION Source Type: research